<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449410</url>
  </required_header>
  <id_info>
    <org_study_id>SPACE1</org_study_id>
    <nct_id>NCT00449410</nct_id>
  </id_info>
  <brief_title>Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients</brief_title>
  <acronym>SPACE</acronym>
  <official_title>Silent Cerebrovascular Lesion and Cognitive Decline Prevention in Atrial Fibrillation by Intensive Cholesterol Lowering in Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In elderly patients with atrial fibrillation (AF) the presence of silent brain infarcts and
      neurocognitive deficit is high despite adequate treatment with oral anticoagulation.
      Atherosclerosis is considered to be a chronic inflammatory disease and thrombosis and
      inflammation are strongly correlated. Atrial fibrillation is linked with increased levels of
      inflammatory markers and intensive cholesterol lowering has proven to reduce inflammation. In
      a prospective double-blind randomized pilot-study we want to test the hypothesis, that
      addition of intensive cholesterol lowering treatment besides adequate oral anticoagulation
      will reduce cerebrovascular lesions and will be beneficial for neurocognitive status in
      elderly AF patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date>October 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive function</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebrovascular lesions on MRI</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of inflammatory markers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of hemostatic markers</measure>
  </secondary_outcome>
  <enrollment>35</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Neuropsychology</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <condition>Inflammation</condition>
  <condition>Hemostasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elderly patients (&gt;68 and &lt;82 years) with atrial fibrillation and adequate oral
             anticoagulation therapy and cholesterol levels between 4,5 mmol/l and 7 mmol/l

        Exclusion Criteria:

          -  Indication for cholesterol lowering treatment according to Dutch CBO-cholesterol
             guidelines (2004)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>68 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Kuilenburg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCN Radboud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gheorghe AM Pop, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>UMCN Radboud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gheorghe AM Pop</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2007</study_first_submitted>
  <study_first_submitted_qc>March 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2007</study_first_posted>
  <last_update_submitted>March 19, 2007</last_update_submitted>
  <last_update_submitted_qc>March 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2007</last_update_posted>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>elderly</keyword>
  <keyword>cholesterol lowering</keyword>
  <keyword>neurocognitive function</keyword>
  <keyword>cerebrovascular lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

